Trial · NCT01262820
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
NCT01262820, Phase 2, Completed, UNC Lineberger Comprehensive Cancer Center; results first posted 2016-09-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab. Trials, record NCT01262820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01262820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
- NCT number
- NCT01262820
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Conditions
- Lung Cancer
- Interventions
- Pazopanib
- First posted
- 2010-12-17
- Last updated
- 2017-03-07
- Results first posted
- 2016-09-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control Rate | Eight (8) months w additional time for response date to mature (up to 2 years per participant) | Response (CR + PR + SD) as defined by RECIST v1.1 lasting equal to or greater than 12 weeks in patients treated with pazopanib alone for stage IIIB/IV non-squamous NSCLC after progression on first line therapy containing bevacizumab Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) : Complete Response (CR) is defined as Disappearance of all target lesions; Partial Response (PR), as a \>=30% decrease in the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) of all target lesions; Progression, as a 20% increase in the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) of all target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. Target lesions are representative of all involved organs and measurable by radiographic imaging. |
| Secondary | Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1 | 8 months with additional time for response to mature (up to 2 years per participant) | Estimate of combined response rate (Complete Response (CR) + Partial Response (PR) per RECIST v1.1 Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) : Complete Response (CR) is defined as the disappearance of all target lesions and Partial Response (PR) as a \>=30% decrease in the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) of all target lesions.Target lesions are representative of all involved organs and measurable by radiographic imaging. |
| Secondary | Progression Free Survival | Eight (8) months w additional time for response data to mature (up to 2 years per participant) | Progression free survival is defined as time of enrollment until disease progression or death Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) : Progression is defined as a 20% increase in the sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) of all target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Target lesions are representative of all involved organs and measurable by radiographic imaging. |
| Secondary | Overall Survival | Eight (8) months w additional time for response date to mature (up to 2 years per participant) | Overall survival is defined as the time of enrollment until death |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease Control Rate | Eight (8) months w additional time for response date to mature (up to 2 years per participant) | % of participants with disease control | NUMBER | |
| SECONDARY | Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1 | 8 months with additional time for response to mature (up to 2 years per participant) | participants | NUMBER | |
| SECONDARY | Progression Free Survival | Eight (8) months w additional time for response data to mature (up to 2 years per participant) | weeks | MEDIAN | |
| SECONDARY | Overall Survival | Eight (8) months w additional time for response date to mature (up to 2 years per participant) | weeks | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Control Rate | Single Intervention | 13 | 95% Confidence Interval 2 to 40 | % of participants with disease control | |
| Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1 | Single Intervention | 0 | participants | ||
| Progression Free Survival | Single Intervention | 10.9 | 95% Confidence Interval 8.1 to 18.9 | weeks | |
| Overall Survival | Single Intervention | 24.1 | 95% Confidence Interval 20.3 to 33.7 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Single Intervention | 15 | |
| Overall Study | COMPLETED | Single Intervention | 0 | |
| Overall Study | NOT COMPLETED | Single Intervention | 15 |
Source ClinicalTrials.gov
Adverse events68
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Single Intervention | 2 | 15 | 2 |
| other | Alanine Aminotransferase Increased | Investigations | Single Intervention | 3 | 15 | 6 |
| other | Alkaline Phosphatase Increased | Investigations | Single Intervention | 3 | 15 | 4 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Single Intervention | 2 | 15 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Single Intervention | 2 | 15 | 3 |
| other | Anorexia | Metabolism and nutrition disorders | Single Intervention | 9 | 15 | 9 |
| other | Anxiety | Psychiatric disorders | Single Intervention | 2 | 15 | 2 |
| other | Aspartate Aminotransferase Increased | Investigations | Single Intervention | 5 | 15 | 8 |
| other | Blood Bilirubin Increased | Investigations | Single Intervention | 1 | 15 | 2 |
| other | Constipation | Gastrointestinal disorders | Single Intervention | 2 | 15 | 2 |
1 to 10 of 68Source ClinicalTrials.gov
See all 68 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Single Intervention | ||
| Total, other adverse events | Single Intervention | 13 | 15 |
| Total, serious adverse events | Single Intervention | 5 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01262820
GET https://conductscience.org/api/trials/v1/NCT01262820/events?page=2